Clinical Trial

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

Name: SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction — clinical trial record (NCT07597902)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SHIELD

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Trial Details

NCT Number	NCT07597902
Lead Sponsor	Icahn School of Medicine at Mount Sinai
Conditions	Post-acute Sequelae of COVID-19, Long COVID
Enrollment	150 participants
Start Date	2026-06-01
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-19